For adult patients with chronic gout refractory to conventional treatments to address their significant urate burden1
COMPLETE RESOLUTION IS POSSIBLE IN MONTHS, NOT YEARS2
OPEN THEM TO THE POSSIBILITY OF COMPLETE RESOLUTION IN MONTHS, NOT YEARS2
In the pivotal clinical trials for KRYSTEXXA42%
of patients had a complete serum uric acid (sUA) response and met the primary endpoint of maintaining sUA <6 mg/dL for ≥80% of the time in months 3 and 61,345%
of patients had complete resolution of at least 1 target tophus, with no new or progressive tophi, in 6 months1,2See more data
A Nephrologist’s Experience Prescribing KRYSTEXXA
Hear Dr. Payam Shakouri share the story of his first patient he treated with KRYSTEXXA.Watch video
EXPLORE THE UNIQUE MOA OF KRYSTEXXA
KRYSTEXXA has a different mechanism of action compared to oral urate-lowering therapies. See how KRYSTEXXA works and how its unique mechanism of action relates to the kidneys.See the MOA
Horizon Patient Services
Support for you and your patients
Our team is ready to connect all the dots so that your office and your patients have what they need. From personal assistance for your patients to reimbursement support for your office, we take pride in quick and careful service.
Monday – Friday, 8 AM to 8 PM ET
- KRYSTEXXA (pegloticase) [prescribing information] Horizon.
- Baraf HS, et al. Arthritis Res Ther. 2013;15(5):R137.
- Sundy JS, et al. JAMA. 2011;306(7):711-720.